Doç. Dr. Mutlu Hızal
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Lung Neoplasms 10 publicationsSource: OpenAlex / PubMed MeSHView publications
- Breast Neoplasms 8 publications
- Carcinoma, Non-Small-Cell Lung 7 publications
- Carcinoma, Renal Cell 7 publications
- Kidney Neoplasms 7 publications
- Colorectal Neoplasms 3 publications
- Stomach Neoplasms 3 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyMedical Oncologysaglik.gov.trFrom source
- InstitutionAnkara Bilkent Şehir Hastanesisaglik.gov.trFrom source
- Area of workLung NeoplasmsExtracted from 10 publications · Model version —From source
- Publications101 publicationsOpenAlexFrom source
- ORCID0000-0001-5147-4431ORCIDFrom source
- Last synchronised7 November 2026 00:02https://ankarasehir.saglik.gov.tr/TR-331078/tibbi-onkoloji-klinigi-doktorlarimiz.html#mutlu-hizalsaglik.gov.tr
Scientific work
Publications on Lung Neoplasms
-
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)
Clinical & Translational Oncology, 2026
DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source: OpenAlex
-
Long-Term Outcomes of Patients Undergoing Conversion Surgery After Induction Chemotherapy: Turkish Oncology Group Study
Medicina, 2025
DOI 10.3390/medicina61050776 PMID 40428735 Open-access full textSource: OpenAlex
-
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program
BMC Cancer, 2025
DOI 10.1186/s12885-025-15287-2 PMID 41275151 Open-access full textSource: OpenAlex
-
HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy
Turkish Journal of Clinics and Laboratory, 2025
DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Open-access full textSource: OpenAlex
-
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Clinical Breast Cancer, 2025
DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 citations (Europe PMC) Open-access full textSource: OpenAlex
-
Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study
International Journal of Cancer, 2025
DOI 10.1002/ijc.70169 PMID 41045097 3 citations (OpenAlex) Source: OpenAlex
-
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer
Expert Review of Anticancer Therapy, 2025
DOI 10.1080/14737140.2025.2490289 PMID 40200428 3 citations (OpenAlex) Source: OpenAlex
-
Large Unstained Cells: A Predictive Biomarker for Recurrence and Survival in Resected Gastric Cancer
Medicina, 2025
DOI 10.3390/medicina61020208 PMID 40005326 1 citation (OpenAlex) Open-access full textSource: OpenAlex
-
Prognostic Significance of ARID1A, PTEN and PD-L1 Expressions and MMR Status in Colorectal Cancer Tissue
Journal of Oncological Sciences, 2025
DOI 10.37047/jos.galenos.2025.2024.103340 Open-access full textSource: OpenAlex
-
Immunotherapy for Small Cell Lung Cancer
Springer eBooks, 2025
DOI 10.1007/978-3-032-00769-8_244 Source: OpenAlex